Steering CAR T cells to distinguish friend from foe.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed.

1. Auto-inducible expression of chimeric antigen receptor T cells using the NR4A1 promoter.Immunology and cell biology · 2026
   Article
2. Claudin18.2 as a Promising Therapeutic Target in Gastric Cancer.Cells · 2025
   Review
3. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
   Review
4. The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management.Advanced pharmaceutical bulletin · 2024
   Review
5. Therapeutic Immunomodulation in Gastric Cancer.Cancers · 2024
   Review
6. The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape.Frontiers in immunology · 2024
   Review
7. Anti-Cancer Potential of Transiently Transfected HER2-Specific Human Mixed CAR-T and NK Cell Populations in Experimental Models: Initial Studies on Fucosylated Chondroitin Sulfate Usage for Safer Treatment.Biomedicines · 2023
   Article
8. All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma.Journal for immunotherapy of cancer · 2023
   Article
9. To go or not to go? Biological logic gating engineered T cells.Journal for immunotherapy of cancer · 2022
   Review
10. Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer.Frontiers in immunology · 2022
    Review
11. Neurological Manifestation of SARS-CoV-2 Induced Inflammation and Possible Therapeutic Strategies Against COVID-19.Molecular neurobiology · 2021
    Review
12. CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.Cellular oncology (Dordrecht, Netherlands) · 2021
    Review
13. Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs.Translational oncology · 2021
    Review
14. Implementing Logic Gates for Safer Immunotherapy of Cancer.Frontiers in immunology · 2021
    Review
15. CAR-NK Cells: From Natural Basis to Design for Kill.Frontiers in immunology · 2021
    Review
16. The Transcriptomic Analysis of NSC-34 Motor Neuron-Like Cells Reveals That Cannabigerol Influences Synaptic Pathways: A Comparative Study with Cannabidiol.Life (Basel, Switzerland) · 2020
    Article
17. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.International journal of molecular sciences · 2020
    Review
18. CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.Current research in translational medicine · 2020
    Review
19. CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer.Journal of clinical medicine · 2020
    Review
20. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nature reviews. Clinical oncology · 2020
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as